The biopic “Michael” crossed $1 billion worldwide on July 14, 2026, after 12 weekends in theatrical release. It’s the second film to reach that milestone in 2026, after Universal/Illumination/Nintendo’s Super Mario Galaxy.

More significantly, “Michael” is the first ever Lionsgate title to achieve this global box office milestone. For a studio known for mid-tier films, horror releases, and character pieces, reaching $1 billion represents an inflection point. Lionsgate bet on a biopic and got a once-a-decade result.

What Made Michael Work

The film connected across geographies in ways that Hollywood studios had written off as unlikely. Biopics are notoriously difficult—they’re not franchises, they don’t come with built-in fanbases, they demand strong acting over spectacle. Yet “Michael” sustained audience interest through week 12. That’s not typical for dramas.

Word of mouth held the film. International territories—where biographical interest in the subject runs deep—pushed hard into that $1 billion. The film also benefited from counterprogramming against franchise fatigue. Audiences wanted something real to watch.

Lionsgate’s Path Forward

The $1 billion result changes Lionsgate’s negotiating position. International distributors see that audiences will show up for prestige dramas. The studio can point to “Michael” as proof of concept for its mid-budget theatrical strategy. That matters for greenlit scripts sitting in development hell.

Most biopics don’t cross $500 million worldwide. They play strongly domestically, underperform internationally. “Michael” reversed that math. Whether it’s repeatable is another question—the subject matter, the talent, the timing all aligned.

When a biopic holds audiences through 12 weekends and reaches a billion, the industry has to recalibrate what it thinks is possible at this scale.

FYI (keeping you in the loop)

How rare is $1 billion for non-franchise films?

Very rare. Most billion-dollar films are sequels, superhero movies, or established IPs. Only a handful of original films reach it. Biopics almost never do. Michael is an outlier that will reshape greenlight decisions.